Key points are not available for this paper at this time.
Ibrutinib was associated with significantly increased risks of both hypertension and atrial fibrillation.
Caldeira et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: